Frequently Asked Questions

General FAQs

Who is Isodiol's transfer agent?

Isodiol's transfer agent is Computershare Trust Company of Canada.
Toronto Office Address: 
100 University Ave, 8th Floor
Toronto, ON
M5J 2Y1 
Phone: 1-888-453-0330

Who does Isodiol's fiscal year end?

March 31

How do I transfer my units or change my address?

Investors may transfer their units or change their address through Computershare, Isodiols’s transfer agent.

Toronto Office Address: 
100 University Ave, 8th Floor
Toronto, ON
M5J 2Y1 
Phone: 1-888-453-0330

How do I buy or sell Isodiol's shares?

Shares must be purchased on the open market through a broker or an online trading platform. Isodiol trades under ISOL, in Canada ISOLF in the United States of America, and  LB6B.F in Germany. 
Shares cannot be purchased directly from the company.

On what stock does Isodiol's shares trade?

Isodiol's shares trade on the CSE in Canada, OTCQB in the United State, and FSE in Germany.

 

How do I get access to financial statements?

Isodiol’s financial statements can be found by searching Isodiol through sedar.com.

 

 

I lost my share certificate. What do I do?

If you have lost your share certificate, contact Computershare, Isodiol's transfer agent.
Toronto Office Address:

100 University Ave, 8th Floor
Toronto, ON
M5J 2Y1 
Phone: 1-888-453-0330

How do I do research on your company?

Research on Isodiol can be done through sedar.com or the thecse.com

When is your next Annual General Meeting (AGM)?

Q2 2019

How do I vote my shares?

A proxy will be mailed prior to the next AGM

Who is your auditor?

Davidson & Company LLP
Chartered Professional Accountants

Where do I find a list of Isodiol's press releases?

Isodiol's press releases can be found at: isodiol.com/news/

How do I exercise my warrants?

Warrants are exercised through Computershare, Isodiol's transfer agent.
Toronto Office Address: 

100 University Ave, 8th Floor
Toronto, ON
M5J 2Y1 
Phone: 1-888-453-0330

How do I find the company's current share price?

Isodiol's current share price can be found on isodiol.com/investors/

Operational FAQs

Why is Isodiol transferring its intellectual property to World Holdings Inc. in Wyoming?

Isodiol’s primary operating subsidiary, Iso International LLC, is a Wyoming limited liability company and has been since it was acquired by Laguna Blends Inc. (which later became Isodiol International Inc.). Wyoming does not have a corporate state income tax. As a result, qualifying companies and activities, particularly those that do not require brick-and-mortar activities in an alternate taxable jurisdiction, may benefit from this favorable tax treatment if they are organized in Wyoming. For example, revenues derived from the licensing of intellectual properties and passive investment activities may be eligible for this favorable tax treatment. Therefore, Isodiol has endeavored to shield current and future revenues from its intellectual properties from legally avoidable taxation by holding them in a Wyoming corporation. Notably, similar tax planning is achieved by other Isodiol subsidiaries that are located in Florida and Nevada, which were formed in those states because of local brick-and-mortar operations and their respective corporate state income tax exemptions.

What is the status of Isodiol’s relationship with Bomi Joseph (a/k/a Moses S. Joseph), Peak Health, ImmunAG, and hops-derived CBD?

Related Update : The civil litigation between Peak Health and Carlsbad Naturals LLC (previously d.b.a. CBD Naturals) has been settled in its entirety as of March 22, 2019.

Iso International LLC ("Iso") entered into a Distribution Agreement with Peak Health, a California non-profit corporation, effective as of November 13, 2017. That agreement granted Iso the sole license to distribute certain products in Australia, Canada, China, Germany, Indonesia, South America, South Korea, Thailand, United Kingdom, and the United States of America. The products included various purportedly hops-derived CBD ingredients and ImmunAG.

In March 2018, Isodiol senior executives and legal counsel traveled to the Peak Health offices to meet with Bomi Joseph for the purpose of addressing certain concerns Isodiol had with Mr. Joseph’s personal credibility. Subsequent to that meeting, Mr. Joseph sent a one sentence e-mail to Isodiol stating that Isodiol was in breach of the Distribution Agreement, which was followed by a formal notice of termination letter from Peak Health’s legal counsel on April 11, 2018.

Isodiol disputes the alleged breaches of the Distribution Agreement and was entitled to sixty (60) days in which to cure any such breaches per the terms of the Distribution Agreement. At this point, while Iso agrees that the Distribution Agreement has terminated, Iso disputes the date of termination. Under the terms of the Distribution Agreement, Isodiol was permitted to sell ImmunAG for six (6) months following its termination.

It is the opinion of Isodiol that Mr. Joseph and Peak Health sought to terminate their relationship with Iso because of the March 2018 confrontation of Mr. Joseph by Isodiol executives and legal counsel concerning his multiple personal identities and criminal past. This is a summary of who Mr. Joseph really is.

Bomi Joseph (D.O.B. 05/31/1959) is a very intelligent and compelling individual. He is remarkably knowledgeable about phyto-based remedies and the science involved in them. He also is, by most accounts, an impressive person to meet and hear lecture.

However, Mr. Joseph also is a notorious con man and criminal who goes by many aliases, including: (i) Bomi Boban Joseph; (ii) Moses Sunith Prasad Joseph [with two ‘s’s in Moses and one ‘s’ in Prasad]; (iii) Mosses Sunith Prasad Joseph [with three ‘s’s in Mosses and one ‘s’ in Prasad]; (iv) Moses Sunith Prassad Joseph [with two ‘s’s in Moses and two ‘s’s in Prassad]; and (v) Moses S. Joseph, which is the name he most frequently used in his previous professional life.

Mr. Joseph has a history of birth record disputes, citizenship disputes, civil litigation, bankruptcy litigation, and multiple criminal indictments and convictions, several of which arose out of his role as the promotor of a multi-million-dollar criminal Ponzi scheme for which he served several years in prison.

Isodiol confirmed these facts by contacting the prosecutor in his prior criminal cases who confirmed that the same person who was convicted of those crimes is the Bomi Joseph who operates Peak Health. Isodiol also obtained a booking photo of Mr. Joseph from his prior criminal arrests and visually verified that the same person convicted of those crimes is the Bomi Joseph who operates Peak Health. Examples of his charges for grand theft and securities fraud can be found in the case styled The People of the State of California vs. Moses S. Joseph, Superior Court of California, County of Santa Clara (DA No 050513356) (06/23/2008). See also:
• https://bits.blogs.nytimes.com/2008/09/02/venture-fund-manager-was-con-man-who-stole-20-
million/
• https://www.sccgov.org/sites/da/newsroom/newsreleases/Pages/NRA2006/charges-against-
moses-joseph.aspx
• https://www.leagle.com/decision/incaco20110128041

Mr. Joseph concealed his identity and his past crimes by legally changing his name in the Second Judicial District Court for the State of Nevada, County of Washoe, pursuant to a petition filed by him on November 29, 2016 (Case No: CV16-02440, Dept. 8) (the “Name Change Case”). This exercise was especially effective at concealing his true identity because he changed the spelling of his former name in the required public notice such that anyone who conducted a search of his incorrect former name would not find his prior convictions and related news articles. Specifically, he stated that his then-current name was Mosses Sunith Prasad Joseph with three ‘s’s in Mosses. Those notices were published in the Legals section of the Sparks Tribune on December 6 and December 20, 2016.

From Isodiol’s perspective, these issues started to be revealed around the time Mr. Joseph solicited Isodiol’s investment of US$10 million into his purported India project. Isodiol sought to visit the project with Mr. Joseph in India but to no avail. In each instance, Mr. Joseph told a story of how he recently discovered that his parents had lied to him about where he was really born and that he had a fraudulent birth certificate and that these circumstances caused the U.S. Department of State to put a hold on his passport. Subsequently, Isodiol discovered that he had filed a lawsuit against the U.S. Department of State demanding the issuance of a passport to him. That case is styled Joseph v. Tillerson et al., U.S. District Court, California Northern District (Oakland) (Case No. 4:2018cv00489), filed on January 22, 2018 (the “Passport Civil Case”).

In the Passport Civil Case, Mr. Joseph repeated the same misrepresentation of his true identity. A detailed comparison of the original complaint and his amended complaint reveals that he removed the following statement: “In or around 2010[, Bomi] was involved with a controversy concerning a contract dispute. Ultimately he was convicted and served four years.” (Passport Civil Case, Doc. 2, Complaint ¶ 13). That sentence was stricken from his amended complaint. There is obvious absurdity in the statement that a person was convicted of a crime and served four years as the result of a contract dispute.

In addition, Mr. Joseph alleged in the original complaint that he was issued a U.S. passport in the name of “Moses Sunith Prasad Joseph.” (Passport Civil Case, Doc. 2, Complaint ¶ 14). However, in his amended complaint, he revised that same sentence to allege that he was issued a U.S. passport in the name of “Moses Sunith Prassad Joseph.” (Passport Civil Case, Doc. 9, Amended Complaint ¶ 14). In that revision, he added an extra ‘s’ in Prassad in the same way that he added an extra ‘s’ to Mosses in the Name Change Case. This spelling change was an intentional revision to the amended complaint in the same way that he obfuscated his name in the Name Change Case.

The Passport Civil Case came to a halt and was stayed when the U.S. Department of Justice obtained a felony criminal indictment against Mr. Joseph for “False Statement in Application for Passport” (18 U.S.C. §1542). That case is styled United States of America v. Bomi Boban Joseph a/k/a Moses Sunith Prasad Joseph, U.S. District Court, California Northern District (San Jose) (Case No. 5:18-cr-00350-BLF-1), filed on August 2, 2018 (the “Passport Criminal Case”). Mr. Joseph pled guilty to the sole count of the indictment on January 22, 2019. His sentencing is scheduled for April 23, 2019.

There are no fewer than ten (10) other U.S. civil cases concerning Mr. Joseph’s misdeeds, including claims against him as Moses S. Joseph, by plaintiffs including U.S. Bank, Aerofund Financial, Inc., Bravara Communications Inc., and Eastman Kodak Company. In addition, there was at least one case pending against him in India as of June 7, 2018.

As previously noted, Isodiol executives and legal counsel confronted Mr. Joseph with some of this information in March 2018. Mr. Joseph had legal counsel present with him at that meeting until the subject of his criminal past arose. At that point, he promptly asked his legal counsel to step outside the room so he could discuss the matters with Isodiol outside of her presence, thus concealing these matters from her. Mr. Joseph vehemently denied that he was the same person as the convicted felon of the same name with the same personal history. Unfortunately, Isodiol had not yet obtained the booking photo from his prior criminal conviction or spoken to the prosecutor in his criminal case at that time or had the benefit of the additional documents filed in the Passport Civil Case and Passport Criminal Case.

Shortly after purportedly terminating the Distribution Agreement with Iso, Mr. Joseph and Peak Health announced a “partnership” with Medical Marijuana Inc. (OTC:MJNA) to “Sell First-Ever And Only Hops-Derived Cannabidiol (CBD) Product, ImmunAG™” on June 26, 2018. According to that news release, ImmunAG is being sold by MJNA “as Real Scientific Humulus Oil (RSHO-K) by Medical Marijuana, Inc.'s distribution subsidiary, HempMeds®.” That product was available for sale on MJNA’s website as of February 20, 2019.

Isodiol does not believe it is in possession of any information that directly contradicts Mr. Joseph’s or Peak Health’s claims that the CBD contained in the ImmunAG they sold to Iso was obtained from a source other than the hops strains represented by Peak Health. However, Isodiol determined that the short-term regulatory benefit to using CBD from hops instead of hemp did not outweigh the inherent risk of doing business with a person who was convicted of felony fraud against major established corporations for millions of dollars.

Isodiol is fortunate to have made the business decision to exit hops-derived CBD before getting further involved with Mr. Joseph and Peak Health. We hope this new information will help our stakeholders further understand Isodiol’s positions to date.

Were there any monetary consequences for divesting Kure Corp.?

The Company funded Kure Corp. with cash contributions of $1,725,000, and the former Kure shareholders received 2,390,952 shares of Isodiol stock. Kure is obligated to repay $500,000 to Isodiol within 120 days of the effective date of the plan or arrangement, which was approved by the court on March 22, 2019. All Kure shareholders who sold Kure shares to Isodiol will receive a pro rata allocation of new Kure shares following the divesture and retain all prior payments of Isodiol stock.

Why did the Company divest Azure Bottling LLC?

The Company has adopted a general business strategy of focusing on brands, product development, and sales, while divesting of the majority of its non-strategic manufacturing and resource-intensive operations. The Company retained a preferential reservation of capacity with Azure Bottling LLC so that it can cost effectively source its CBD water products for the East Coast distribution while eliminating the operating burden and adding $1,000,000 cash to its balance sheet and foregoing approximately $500,000 in future capital commitments.

Will the Company raise additional working capital through private placements to meet their obligations?

The Company may continue to rely on capital financing from time to time until it is able to establish profitable operations. However, the Company anticipates that a substantial portion of its capital needs will be funded by certain capital asset divestitures and a shift toward finished goods revenues with higher profit margins.

What comprises the assets reported in the 3Q2019 financial statements totaling $132,444,395?

These assets consist primarily of goodwill associated with the Company's share issuances for BSPG Laboratories Ltd. and Kure Corp., valued at the then-applicable stock price. The goodwill is allocated on the Canadian parent company’s books and records.

What are the current requirements for an up-list to NASDAQ?

https://listingcenter.nasdaq.com/assets/initialguide.pdf

Does the Company make Form 7 filings with SEDAR in Canada?

Monthly Progress Reports (Form 7) are posted before the opening of trading on the fifth trading day of each month.

Where is Purodiol and Isodiolex sold?

The Company has received regulatory approval for both products in Brazil for multiple conditions, and the products are available on the Special Category List for alternative therapies prescribed by doctors and neurologists. Purodiol also is on the Specials List in the U.K.** and Brazil.

What is C3 Global Biosciences?

C3 markets the product line called exogen™, which was developed for physicians and health care professionals to offer their patients.

Who are Isodiol’s contract manufacturing customers?

The Company only publicly discloses its business relationships when agreed by both parties. Most of our contract manufacturing agreements contain confidentiality provisions.

What is BSPG Laboratories Ltd. and its Active Pharmaceutical Ingredient (API)?

BSPG Laboratories Ltd., is a U.K.-based subsidiary of Isodiol that manufactures Good Manufacturing Practices (GMP) compliant pure, natural CBD containing no THC, which has been approved as an Active Pharmaceutical Ingredient (API) by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The API CBD is a non-synthetic CBD for use in pharmaceutical applications, such as the manufacture of Finished Pharmaceutical Products (FPPs), as well as in research and clinical studies on a global level.

What is the connection between Isodiol and Chemisis other than having the same location in Canada for corporate offices?

Chemesis is a contract manufacturing customer of Isodiol and a supplier of raw materials and cannabidiol ingredients to Isodiol.